Wednesday, June 8, 2011

Stock Market Update on Cairn India for 4QFY2011


Cairn India (CIL) reported higher-than-expected net profit of `2,458cr for 4QFY2011, driven by better-than-expected operating profit on account of lower operating expenditure during the quarter. Further, lower-than-expected interest cost and tax rate resulted in bottom line coming in above our estimates. We maintain our Neutral view on the stock.
Mangala production drives growth: CIL reported a 428% yoy increase in
its top line to `3,654cr (`693cr) in 4QFY2011. Gross production at the Mangala field stood at an average 118,151bpd in 4QFY2011. Current production from the field is hovering around 125,000bopd and is waiting for approval to ramp up to its potential of 150,000bpd. During the quarter, crude oil realisations registered an increase of 32.7% yoy to US$94.2/bbl (US$71/bbl).
Outlook and valuation: We expect earnings to improve in the coming quarters with Train-4 lined up for production, subject to approvals from management and the operating committee. However, the stock price seems to have factored in these positives. We are concerned about the resolution of the royalty issue in favour of ONGC. We are also skeptical about other regulatory issues bothering the Cairn-Vedanta deal. However, there are various exploratory upsides untapped in Barmer Hills and other fields waiting to be developed and commercialised. Further, operational visibilities and major finds in these fields could trigger our valuation upwards. We remain Neutral on the stock with an SOTP fair value of `355

Stock Market Flash on Sun Pharma for 4QFY2011


4QFY2011 Financials Snapshot:   
                                                                   
(`cr)
4QFY2011
3QFY2011
% chg
qoq
4QFY2010
% chg
yoy
Net sales
1,463
1,601
(8.6)
1,080
35.5
Other income
111
58
90.9
14
707.4
Gross profit
1,150
1,169
(1.6)
814
41.3
Operating profit
444
441
0.7
419
6.0
Net profit
443
350
26.4
394
12.2

4QFY2011 Financials Actual V/s Estimates :

`cr
Actual
Estimates
Var(%)
Net sales
1,463
1,412
3.6
Other income
111
71
55.5
Operating profit
444
400
10.8
Tax
2
51
(95.6)
Adj net profit
443
331
33.9


4QFY2011 Consolidated Financial Result Highlights-  

·         The Net Sales for the quarter under review for the company stood at `1,463cr (`1,081cr) an increase of 35.5% yoy, higher than our estimates of `1412cr majorly led by the higher than expected exports at `869cr (`494cr), increase of 75.7% during the quarter. The formulation segment on the export front clocked a robust growth of 98.5% yoy at `776cr (`391cr).
·         The Net sales for Taro for Jan-Mar 2011 is at US$107.7 million, a growth of 21% yoy. The net profit for the quarter is at US$ 25.7 million, higher by 199% when compared to the same quarter last year.
·         The domestic formulations sales came in at `588.7cr (`489.8cr) increase of 20.2% yoy.
·         The company reported gross margins higher than our estimates at 78.6% (76%) for the quarter. However, the employee and other expenses grew by 119% yoy to `254cr (`116cr) and 61.9% yoy to `453cr (`279.5cr) respectively. As a result the OPM contracted to 30.3% (38.7%).
·         The Net profit came in at `504cr (`392cr), growth of 28.7% yoy. The adjusted net profit grew by 12.2% yoy at `443cr (`394cr), higher than our estimate of `331cr.
·         For the full year, the net sales increased by 42.8% yoy to `5,72cr (`4,007cr). The adjusted net profit grew by 34.4% yoy to `1,816cr (`1,351cr).
If you want to buy shares then open demat account in india
4QFY2011 Consolidated Financial Performance:

Y/E March (`cr)
4QFY2011
3QFY2011
% chg
qoq
4QFY2010
% chg yoy
FY2011
FY2010
% chg yoy
Net sales
1,463
1,601
(8.6)
1,080
35.5
5,721
4,007
42.8
Other income
110.8
58.0
90.9
13.7
707.4
272.7
205.3
32.8
Total income
1,574
1,659

1,094
43.9
5,994
4,213
42.3
Gross profit
1,150
1,169
(1.6)
814
41.3
4,261
2,910
46.44
Gross margin (%)
78.6
73.0

75.4

74.5
72.6

Operating profit
444
441
0.7
419
6.0
1,967
1,363
44.3
Operating margin (%)
30.3
27.5

38.7

34.4
34.0

Interest
0
0
-
0

0
0
-
Depreciation
48
80
(40.1)
42
14.9
204
153
33.1
PBT
506
418
21.1
390
29.7
2,036
1,415
43.9
Provision for taxation
2
54
(95.9)
(1)
(277.8)
128
68
89.3
PAT before extra-ordinary item
504
364
38.6
392
28.7
1,907
1,347
41.6
Minority interest(MI)
(61)
(13)
-
3
-
(91)
4

Extraordinary item
0
0

0

0
0

PAT after extra-ordinary item & MI
443
350
26.4
394
12.2
1,816
1,351
34.4
EPS (`)
4.3
3.4

3.8

17.5
13.0


 
At CMP, the stock is currently trading at 22.7x FY2012E and 18.5x FY2013E earnings. We would revise our estimates post the interaction with the management.
Key financials:
Valuation Summary





Y/E March (`cr)
FY2009
FY2010
FY2011E
FY2012E
FY2013E
Net sales
4,273
4,103
5,721
7,627
9,550
% chg
27.3
(4.0)
39.4
33.3
25.2
Net profit
1,818
1,351
1,816
2,030
2,492
% chg
20.7
(25.7)
34.4
11.8
22.7
EPS (`)
17.6
13.0
17.5
19.6
24.1
EBITDA Margin (%)
43.6
33.2
34.4
29.1
29.8
P/E (x)
25.4
34.1
25.4
22.7
18.5
RoE (%)
30.2
17.8
19.3
19.9
20.8
RoCE (%)
27.4
15.3
18.3
19.0
21.1
P/BV (x)
6.5
5.7
4.9
4.2
3.6
EV/Sales (x)
10.4
10.7
7.7
5.8
4.5
EV/EBITDA (x)
23.9
32.3
23.9
19.8
15.2